Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENMD-2076 in Triple-Negative Breast Cancer
NCT01639248Phase 2Completed
- Sponsor
- CASI Pharmaceuticals, Inc.
- Start
- Jul 2012
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of enmd-2076 in triple-negative breast cancer (TNBC), sponsored by CASI Pharmaceuticals, Inc.. Started Jul 2012; status: completed.
02
Drugs
enmd-2076
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01639248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01639248.